FibroGen (FGEN) Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last year. There are currently 2 sell ratings and 4 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" FGEN shares.
View FGEN analyst ratings or view top-rated stocks.

6 brokerages have issued 1 year price targets for FibroGen's stock. Their FGEN share price forecasts range from $2.00 to $35.00. On average, they predict the company's stock price to reach $22.00 in the next twelve months. This suggests a possible upside of 2,415.4% from the stock's current price.
View analysts price targets for FGEN or view top-rated stocks among Wall Street analysts.

FibroGen's stock was trading at $16.02 at the beginning of 2023. Since then, FGEN shares have decreased by 94.5% and is now trading at $0.8746.
View the best growth stocks for 2023 here.

FibroGen saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 10,810,000 shares, a decline of 5.7% from the August 15th total of 11,460,000 shares. Based on an average trading volume of 3,950,000 shares, the short-interest ratio is currently 2.7 days. Currently, 11.9% of the company's shares are short sold.
View FibroGen's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our FGEN earnings forecast.

FibroGen, Inc. (NASDAQ:FGEN) announced its earnings results on Monday, August, 7th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.07. The biopharmaceutical company earned $44.32 million during the quarter, compared to analysts' expectations of $34.17 million. FibroGen had a negative trailing twelve-month return on equity of 879.75% and a negative net margin of 246.75%.

Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy (GTE), Allergan (AGN) and ALJ Regional (ALJJ).

(FGEN) raised $146 million in an initial public offering on Friday, November 14th 2014. The company issued 8,100,000 shares at a price of $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners acted as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

FibroGen's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include State Street Corp (5.11%), Schroder Investment Management Group (3.42%), Geode Capital Management LLC (1.90%), Assenagon Asset Management S.A. (1.52%), Affinity Asset Advisors LLC (0.00%) and Goldman Sachs Group Inc. (0.90%). Insiders that own company stock include Benjamin Cravatt, Christine Chung, Enrique A Conterno, James A Schoeneck, Jeffrey William Henderson, Juan Graham, K Peony Yu, Kalevi Kurkijarvi, Mark Eisner, Pat Cotroneo, Thane Wettig and Thomas F Kearns Jr.
View institutional ownership trends.

Shares of FGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FGEN stock can currently be purchased for approximately $0.87.

FibroGen (NASDAQ:FGEN) has a market capitalization of $85.89 million and generates $140.73 million in revenue each year. The biopharmaceutical company earns $-293,650,000.00 in net income (profit) each year or ($3.39) on an earnings per share basis.

The company employs 592 workers across the globe.

FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The official website for the company is www.fibrogen.com. The biopharmaceutical company can be reached via phone at (415) 978-1200, via email at ir@fibrogen.com, or via fax at 415-978-1902.